Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous ASCs for Critical Limb Ischemia (ACellDREAM)
NCT01211028Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2009
- Primary completion
- Jul 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in critical limb ischemia (CLI), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Number and Nature of Adverse Events at 6 months. Started Jan 2009; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT01211028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211028.